Thanks to an international collaborative effort, this is, to the authors' knowledge, the largest retrospective study showing the activity of cabozantinib, an oral TKI targeting VEGFR, MET, and AXL, in TRCC. The gene discussed is KDR; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.